Nursing and Health Professions
Cabergoline
100%
Patient
85%
Remission
57%
Diagnosis
42%
Combination Therapy
42%
Neoplasm
42%
Inpatient
42%
Prolactinoma
42%
Treatment Duration
28%
Dopamine Receptor Stimulating Agent
28%
Prolactin
28%
Recurrent Disease
14%
Tumor Volume
14%
Nuclear Magnetic Resonance Imaging
14%
Recurrence Risk
14%
Treatment Response
14%
Cohort Analysis
14%
Hypophysis Adenoma
14%
Woman
14%
Dose
14%
Hospital
14%
Hyperprolactinemia
14%
Drug Withdrawal
14%
Pharmacology, Toxicology and Pharmaceutical Science
Cabergoline
100%
Remission
57%
Neoplasm
42%
Prolactinoma
42%
Dopamine Receptor Stimulating Agent
28%
Prolactin
28%
Hypophysis Tumor
28%
Recurrent Disease
14%
Recurrence Risk
14%
Hypophysis Adenoma
14%
Hyperprolactinemia
14%
Neuroscience
Cabergoline
100%
Prolactinoma
42%
Cavernous Sinus
42%
Dopamine Agonist
28%
Prolactin
28%
Pituitary Tumour
28%
Magnetic Resonance Imaging
14%
Pituitary Adenoma
14%
Predictor
14%
Biochemistry, Genetics and Molecular Biology
Cabergoline
100%
Prolactin
28%
Age
28%
Dopamine Agonist
28%
Tumor Volume
14%
Drug Withdrawal
14%
Dose
14%
Cohort Study
14%
Psychology
Groups
42%
Treatment
42%
Dopamine
28%
Magnetic Resonance Imaging
14%
Assessment
14%
Drug Withdrawal
14%